The use of recombinant factor VIIa in the treatment of bleeding disorders.

Article Details

Citation
Copy to clipboard

Roberts HR, Monroe DM, White GC

The use of recombinant factor VIIa in the treatment of bleeding disorders.

Blood. 2004 Dec 15;104(13):3858-64. Epub 2004 Aug 24.

PubMed ID
15328151 [ View in PubMed
]
Abstract

Recombinant factor VIIa was initially developed for the treatment of hemorrhagic episodes in hemophilic patients with inhibitors to factors VIII and IX. After its introduction, it has also been used "off-label" to enhance hemostasis in nonhemophilic patients who experience bleeding episodes not responsive to conventional therapy. Evidence so far indicates that the use of factor VIIa in hemophilic patients with inhibitors is both safe and effective. Anecdotal reports also suggest that the product is safe and effective in controlling bleeding in nonhemophilic patients. However, its use in these conditions has not been approved by the FDA, and conclusive evidence of its effectiveness from controlled clinical trials is not yet available. Several questions pertaining to the use of factor VIIa require further investigation, including the mechanism of action; the optimal dose; definitive indications; ultimate safety; and laboratory tests for monitoring therapy.

DrugBank Data that Cites this Article

Drugs